Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in

  • 0 views
  • 23 Jan, 2021
  • 1 location
Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma (RbGALOP2)

This protocol provides guidelines for the management of non-metastatic unilateral retinoblastoma and introduces an innovative adjuvant therapy for higher risk patients based upon the results of the Grupo de America Latina de Oncologia Pediatrica (GALOP) I study. Conservative therapy will be not protocolized.

  • 64 views
  • 01 Mar, 2022
  • 1 location
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Depending on the variant of the disease, patients are divided into 3 groups: A, B and C. Group A include patients with acute myeloid leukemia (AML) inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, group B - AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1, AML with normal karyotype with or without gene mutations (FLT3, NPM1, CEBPa) regardless …

  • 0 views
  • 28 Apr, 2022
  • 1 location
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed AML patients. 840 cases are supposed to recruited in 3 years.

ara-c
cladribine
idarubicin
cytarabine
induction chemotherapy
  • 26 views
  • 24 Jan, 2021
  • 1 location
Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following …

venetoclax
cancer
daunorubicin
colony stimulating factor
vosaroxin
  • 42 views
  • 25 Jan, 2021
  • 57 locations
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064)

survival with significantly lower toxicity rates compared to the standard ATRA + idarubicin (AIDA) therapy. Inspired by the results of this trial the investigators intend to perform a randomized study in

secondary mds
myeloid leukemia
tretinoin
mitoxantrone
cytarabine
  • 0 views
  • 07 Apr, 2022
  • 7 locations
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

administration of Bortezomib in patients with B-precursor ALL with initial WBC100,000/l will improve treatment outcome? Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL

lymphoid leukemia
daunorubicin
dexamethasone
adult t-cell leukemia/lymphoma
b-cell acute lymphoblastic leukemia
  • 179 views
  • 23 Jan, 2021
  • 59 locations
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients 60 Years Old

The study will include newly-diagnosed AML patients, not suffering acute promyelocytic leukemia; aged 18-60 years, who are eligible for standard induction chemotherapy. The patients will be randomized to one standard induction regimen (DAC or DA-90). At day seven after completion of induction, a bone marrow aspiration with MRD will be …

cell transplantation
ara-c
myelodysplastic syndromes
induction chemotherapy
secondary acute myeloid leukemia
  • 32 views
  • 07 Oct, 2021
  • 10 locations
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

This phase Ib/II trial studies the side effects and best dose of pevonedistat and to see how well it works in combination with cytarabine and idarubicin in treating patients with acute myeloid

myeloid leukemia
cancer
cytarabine
hydroxyurea
leukemia
  • 1 views
  • 02 Mar, 2022
  • 3 locations
The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol

The aim of this study is to test whether the realization of 3 courses of intra-arterial chemotherapy of idarubicin-lipiodol without embolization, administered non-selectively in the hepatic

prothrombin
neutrophil count
cirrhosis
liver disease
  • 2 views
  • 15 Mar, 2021
  • 1 location